Ignite Creation Date:
2025-12-24 @ 4:45 PM
Ignite Modification Date:
2025-12-29 @ 1:20 PM
Study NCT ID:
NCT01706250
Status:
COMPLETED
Last Update Posted:
2017-08-23
First Post:
2012-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000152', 'term': 'Acne Vulgaris'}], 'ancestors': [{'id': 'D017486', 'term': 'Acneiform Eruptions'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012625', 'term': 'Sebaceous Gland Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D020156', 'term': 'Salicylic Acid'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D001565', 'term': 'Benzoates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006880', 'term': 'Hydroxy Acids'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D010636', 'term': 'Phenols'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '866-435-7343', 'title': 'GSK Response Center', 'organization': 'GlaxoSmithKline'}, 'certainAgreement': {'otherDetails': 'GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From the informed consent taken to up to 4 months', 'description': 'ITT Population. There were no treatment -related adverse events reported during the study, so the data has been reported as an overall, single arm; as the participants used were the same in each arm', 'eventGroups': [{'id': 'EG000', 'title': 'MAXCLARITY II + PROACTIV', 'description': 'This was a split face study, wherein the participants, each morning washed their face with MaxClarity II foam cleanser on 1 side of the face and Proactive renewing cleanser on the other side of the face. The face was patted dry the MaxClarity II foam treatment was applied to the MaxClarity II side of the face and on the proactive side, the participant applied the Revitalizing toner and then the Repairing lotion. The same was repeated in the evening, where the participants washed their face with MaxClarity II foam cleanser on 1 side and Proactiv renewing cleanser on the other side of the face. On the Proactiv side, the participant will apply the Revitalizing toner and then the Repairing lotion.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 5, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.1'}, {'term': 'Skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 11.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% benzyl peroxide \\[BPO\\]) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (the side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wk, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Percent change, IL count', 'categories': [{'measurements': [{'value': '-55.93', 'spread': '32.72', 'groupId': 'OG000'}, {'value': '-52.64', 'spread': '29.23', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, NIL count', 'categories': [{'measurements': [{'value': '-37.97', 'spread': '38.72', 'groupId': 'OG000'}, {'value': '-45.66', 'spread': '23.05', 'groupId': 'OG001'}]}]}, {'title': 'Percent change in TL count', 'categories': [{'measurements': [{'value': '-45.46', 'spread': '27.24', 'groupId': 'OG000'}, {'value': '-47.69', 'spread': '21.92', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.6779', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-3.29', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '32.98', 'groupDescription': 'Percent change for IL count for MAXCLARITY II Vs PROACTIV at Wk 8', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2847', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'paramValue': '7.68', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '29.51', 'groupDescription': 'Percent change for NIL count for MAXCLARITY II Vs PROACTIV at Wk 8', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6894', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'paramValue': '2.24', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '23.35', 'groupDescription': 'Percent change for TL count for MAXCLARITY II Vs PROACTIV at Wk 8', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) and Wk 8', 'description': 'This was an efficacy variable. An expert grader evaluated each side of the face (included forehead, cheeks and chin), the left and the right side, for IL (presence of papules and pustules), NIL (presence of open and closed comedones) and the TLs. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. The evaluator was also blinded. BL was defined as Day 1. The percent change was calculated as the value at Wk 8 minus the value at BL.', 'unitOfMeasure': 'percent change in lesion count', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Intent to treat (ITT) analysis set included data from all randomized participants who received the study drug. The number of participants available at that particular time point were used for analysis.'}, {'type': 'SECONDARY', 'title': 'Mean Percent Change in IL Count From BL (Day 1) to Wks 1, 2 and 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wk. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wk, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Percent change, IL count, BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-17.56', 'spread': '33.63', 'groupId': 'OG000'}, {'value': '-19.93', 'spread': '26.39', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, IL count, BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-35.64', 'spread': '37.66', 'groupId': 'OG000'}, {'value': '-31.64', 'spread': '30.06', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, IL count, BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-21.35', 'spread': '63.62', 'groupId': 'OG000'}, {'value': '-44.99', 'spread': '37.85', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.9909', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '2.38', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '50.10', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: IL count, BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6671', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'paramValue': '-4.0', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '39.91', 'groupDescription': 'IL count for MAXCLARITY II Vs PROACTIV- BL to Wk 2 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0632', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'paramValue': '23.64', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '52.05', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: IL count, BL to Wk 4 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the IL by counting the number of papules and pustules. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of IL) at each individual visit (percent value at wk 1, 2 and 4) minus the value at BL respectively.', 'unitOfMeasure': 'percent change in lesion count', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT used. Only those participants available at the specified time points were analyzed (re presented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Percent Change in NIL Count From BL (Day 1) to Wks 1, 2 and 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Percent change, NIL count, BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.92', 'spread': '32.71', 'groupId': 'OG000'}, {'value': '-7.13', 'spread': '25.91', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, NIL count, BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-24.12', 'spread': '37.73', 'groupId': 'OG000'}, {'value': '-21.07', 'spread': '26.17', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, NIL count, BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-30.26', 'spread': '38.48', 'groupId': 'OG000'}, {'value': '-37.76', 'spread': '22.65', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.7385', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '3.20', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '42.31', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: NIL count, BL to Wk 1 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.7296', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-3.04', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '37.77', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: NIL count, BL to Wk 2 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3774', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'paramValue': '7.50', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '36.11', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: NIL count, BL to Wk 4 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the NIL by the presence of open and closed comedones. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of NIL) at each individual visit (percent value at Wk 1, 2 and 4) minus the value at BL respectively.', 'unitOfMeasure': 'percent change in lesion count', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Percent Change in TL Count From BL (Day 1) to Wks 1, 2 and 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Percent change, in TL count, BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-11.34', 'spread': '21.84', 'groupId': 'OG000'}, {'value': '-13.36', 'spread': '19.07', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, in TL count, BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-31.94', 'spread': '27.86', 'groupId': 'OG000'}, {'value': '-26.19', 'spread': '20.23', 'groupId': 'OG001'}]}]}, {'title': 'Percent change, in TL count, BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-34.17', 'spread': '28.06', 'groupId': 'OG000'}, {'value': '-41.17', 'spread': '20.23', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.7634', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '2.02', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '29.53', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: TL count, BL to Wk 1 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4087', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-5.75', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '29.61', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: TL count, BL to Wk 2 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2455', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '7.00', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '25.40', 'groupDescription': 'Percent change for MAXCLARITY II Vs PROACTIV: TL count, BL to Wk 4 (within group)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the total lesions by the sum of both inflammatory and non-inflammatory lesions on each side (left side and right side). The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of total lesions) at each individual visit (percent value at Wks 1, 2 and 4) minus the value at baseline respectively.', 'unitOfMeasure': 'percent change in lesion count', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=X, X in the category titles).'}, {'type': 'SECONDARY', 'title': "Mean Change in Investigator's Static Global Assessment (ISGA) From BL (Day 1) to Wks 1, 2, 4 and 8.", 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Change, in ISGA from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.31', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.39', 'groupId': 'OG001'}]}]}, {'title': 'Change, in ISGA from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.47', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '-0.21', 'spread': '0.54', 'groupId': 'OG001'}]}]}, {'title': 'Change, in ISGA from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.53', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '-0.42', 'spread': '0.61', 'groupId': 'OG001'}]}]}, {'title': 'Change, in ISGA from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.39', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '-0.39', 'spread': '0.61', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.05', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.39', 'groupDescription': 'Change, in ISGA for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1250', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.26', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.56', 'groupDescription': 'Change, in ISGA for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6250', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.11', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.46', 'groupDescription': 'Change, in ISGA for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.00', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.59', 'groupDescription': 'Change, in ISGA for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "The evaluator (blinded) evaluated the acne severity of the participants' face using the ISGA scale ranging from 0 to 5. The grading was 0= Clear, skin with no IL or NILs; 1= Almost clear, rare NILs with no more than one small IL ; 2= Mild, some NILs with no more than few ILs (papules/pustules only, no nodular lesions); 3= Moderate Upto many NILs and may have some ILs but no more than one small nodular lesion ; 4= Severe, Upto many NILs and ILs but no more than a few nodular lesions; 5= Very severe, many NILS and ILs more than a few nodular lesions, may have cystic lesions. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each visit (Wks 1,2,4 and 8) minus the value at BL respectively.", 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Evaluator Tolerability Assessments-Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-weeks (Wk). The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wk, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Erythema; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.22', 'groupId': 'OG001'}]}]}, {'title': 'Erythema; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '0.32', 'groupId': 'OG001'}]}]}, {'title': 'Erythema; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.40', 'groupId': 'OG001'}]}]}, {'title': 'Erythema; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.42', 'groupId': 'OG000'}, {'value': '0.06', 'spread': '0.42', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.10', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.45', 'groupDescription': 'Change, in Erythema for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Signed Rank', 'paramValue': '0.05', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.23', 'groupDescription': 'Change, in Erythema for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. Erythema is condition characterized by redness or rash on the skin. The assessment of the erythema was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk 4 and Wk 8, and hence statistical analysis was not done.", 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=X, X in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Evaluator Tolerability Assessments-Dryness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Dryness; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.15', 'spread': '0.49', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '0.45', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.11', 'spread': '0.32', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.32', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '1.00', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.05', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.22', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.05', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.23', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the dryness was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at baseline respectively. The change from BL was '0' for Wk 2, Wk 4, and Wk 8 and hence statistical analysis was not done.", 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=X, X in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Evaluator Tolerability Assessments-Peeling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Peeling; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Peeling; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.46', 'groupId': 'OG001'}]}]}, {'title': 'Peeling; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Peeling; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.11', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.46', 'groupDescription': 'Change, in Peeling, for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the peeling was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk (1, 4 and 8) and hence statistical analysis was not done.", 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points were analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Participant Tolerability Assessments-Redness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Redness; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.50', 'spread': '1.00', 'groupId': 'OG000'}, {'value': '0.35', 'spread': '0.81', 'groupId': 'OG001'}]}]}, {'title': 'Redness; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.37', 'spread': '1.01', 'groupId': 'OG000'}, {'value': '0.21', 'spread': '0.79', 'groupId': 'OG001'}]}]}, {'title': 'Redness; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.72', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '0.56', 'spread': '0.86', 'groupId': 'OG001'}]}]}, {'title': 'Redness; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.61', 'spread': '1.14', 'groupId': 'OG000'}, {'value': '0.28', 'spread': '0.75', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.5313', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.15', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.67', 'groupDescription': 'Change, in Redness for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.16', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.60', 'groupDescription': 'Change, in Redness for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.7500', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.17', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.86', 'groupDescription': 'Change, in Redness for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2500', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.33', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.84', 'groupDescription': 'Change, in Redness for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for redness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the redness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.', 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Participant Assessments of Tolerability-Dryness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Dryness; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.20', 'spread': '1.24', 'groupId': 'OG000'}, {'value': '0.90', 'spread': '1.07', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.05', 'spread': '1.39', 'groupId': 'OG000'}, {'value': '0.68', 'spread': '1.16', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.33', 'spread': '1.14', 'groupId': 'OG000'}, {'value': '1.06', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Dryness; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.33', 'spread': '1.24', 'groupId': 'OG000'}, {'value': '1.11', 'spread': '1.02', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.2131', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.30', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.86', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank)', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2656', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.37', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '1.16', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2344', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.28', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.75', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3594', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.22', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.73', 'groupDescription': 'Change, in Dryness for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for dryness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the dryness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.', 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population . Only those participants available at the specified time points we re analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Participant Assessments of Tolerability-Burning', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Burning; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.95', 'spread': '1.28', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '0.85', 'groupId': 'OG001'}]}]}, {'title': 'Burning; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.84', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '0.58', 'spread': '0.84', 'groupId': 'OG001'}]}]}, {'title': 'Burning; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '0.44', 'spread': '0.62', 'groupId': 'OG001'}]}]}, {'title': 'Burning; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.83', 'spread': '1.34', 'groupId': 'OG000'}, {'value': '0.44', 'spread': '0.70', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.6172', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.20', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '1.32', 'groupDescription': 'Change, in Burning for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3984', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'paramValue': '0.26', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.93', 'groupDescription': 'Change, in Burning for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0781', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.56', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '1.10', 'groupDescription': 'Change, in Burning for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3750', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.39', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '1.24', 'groupDescription': 'Change, in Burning for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1,2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for burning. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the burning was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1, 2, 4 and 8) minus the value at BL respectively.', 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Participant Assessments of Tolerability-Itching', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Itching; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.20', 'spread': '0.62', 'groupId': 'OG000'}, {'value': '0.20', 'spread': '0.77', 'groupId': 'OG001'}]}]}, {'title': 'Itching; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.37', 'spread': '1.01', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.62', 'groupId': 'OG001'}]}]}, {'title': 'Itching; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.97', 'groupId': 'OG000'}, {'value': '0.06', 'spread': '0.24', 'groupId': 'OG001'}]}]}, {'title': 'Itching; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.28', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.58', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.00', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.46', 'groupDescription': 'Change, in Itching for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': '[Signed Rank]', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0625', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.32', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.58', 'groupDescription': 'Change, in Itching for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2500', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.28', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.75', 'groupDescription': 'Change, in Itching for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2500', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.17', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.38', 'groupDescription': 'Change, in Itching for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for itching. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the itching was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.', 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=x, x in the category titles).'}, {'type': 'SECONDARY', 'title': 'Mean Change in Each of the Participant Assessments of Tolerability-Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MAXCLARITY II', 'description': 'MAXCLARITY II (2.5% BPO) foam cleanser and foam treatment, 0.5% salicylic acid toner foam were used in this arm, both morning and evening for 8-Wks. The participants in the morning washed their face with MaxClarity II foam cleanser, on 1 side of the face (side of face, where no proactive cleanser and revitalizing toner were used) . The face was patted dry, post which MaxClarity II foam treatment was applied to the MaxClarity II side of the face. The same was repeated in the evening. This was a split face study.'}, {'id': 'OG001', 'title': 'PROACTIV', 'description': 'Proactive renewing cleanser and revitalizing toner and the repairing lotion were used both morning and evening for 8-Wks, for the same participant, from Maxclarity II arm, on the other side. The same participants from the Maxclarity II arm, in the morning washed their face with Proactive renewing cleanser on the other side of the face. The face was patted dry, post which revitalizing toner and then the repairing lotion on the same side cleansed with the proactive cleanser. The same was repeated in the evening. This was a split face study.'}], 'classes': [{'title': 'Scaling; Change from BL to Wk 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.40', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.55', 'groupId': 'OG001'}]}]}, {'title': 'Scaling; Change from BL to Wk 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.26', 'spread': '0.81', 'groupId': 'OG000'}, {'value': '0.16', 'spread': '0.69', 'groupId': 'OG001'}]}]}, {'title': 'Scaling; Change from BL to Wk 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.56', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '0.39', 'spread': '0.78', 'groupId': 'OG001'}]}]}, {'title': 'Scaling; Change from BL to Wk 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.83', 'spread': '1.20', 'groupId': 'OG000'}, {'value': '0.67', 'spread': '1.14', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.5000', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Signed Rank', 'ciPctValue': '95', 'paramValue': '0.15', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.59', 'groupDescription': 'Change, in Scaling for MAXCLARITY II Vs PROACTIV: from BL to Wk 1 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.7500', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Signed Rank', 'ciPctValue': '95', 'paramValue': '0.11', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.57', 'groupDescription': 'Change, in Scaling for MAXCLARITY II Vs PROACTIV: from BL to Wk 2 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4531', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.17', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.62', 'groupDescription': 'Change, in Scaling for MAXCLARITY II Vs PROACTIV: from BL to Wk 4 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6250', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciPctValue': '95', 'paramValue': '0.17', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.86', 'groupDescription': 'Change, in Scaling for MAXCLARITY II Vs PROACTIV: from BL to Wk 8 (within group)', 'statisticalMethod': 'Signed Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for scaling. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the scaling was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.', 'unitOfMeasure': 'units on scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population. Only those participants available at the specified time points we re analyze d (represented by n=X, X in the category titles).'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'MAXCLARITY II + PROACTIV', 'description': 'This was a split face study, wherein the participants, each morning washed their face with MaxClarity II foam cleanser on 1 side of the face and Proactive renewing cleanser on the other side of the face. The face was patted dry the MaxClarity II foam treatment was applied to the MaxClarity II side of the face and on the proactive side, the participant applied the Revitalizing toner and then the Repairing lotion. The same was repeated in the evening, where the participants washed their face with MaxClarity II foam cleanser on 1 side and Proactiv renewing cleanser on the other side of the face. On the Proactiv side, the participant will apply the Revitalizing toner and then the Repairing lotion.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '18'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'A total of 20 participants were enrolled to an evaluator-blinded, split-face study of acne, which was conducted at two centers in United States from 08 September 2009 to 25 January 2010.', 'preAssignmentDetails': 'Same 20 participants were used in the split face study for the 2 interventions namely MaxClarity and Proactiv carried out in a single period.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'MAXCLARITY II + PROACTIV', 'description': 'This was a split face study, wherein the participants, each morning washed their face with MaxClarity II foam cleanser on 1 side of the face and Proactive renewing cleanser on the other side of the face. The face was patted dry the MaxClarity II foam treatment was applied to the MaxClarity II side of the face and on the proactive side, the participant applied the Revitalizing toner and then the Repairing lotion. The same was repeated in the evening, where the participants washed their face with MaxClarity II foam cleanser on 1 side and Proactiv renewing cleanser on the other side of the face. On the Proactiv side, the participant will apply the Revitalizing toner and then the Repairing lotion.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '21.5', 'spread': '3.6', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '16', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Asian', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}, {'title': 'Black', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-09-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-04', 'completionDateStruct': {'date': '2010-01-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-07-19', 'studyFirstSubmitDate': '2012-10-11', 'resultsFirstSubmitDate': '2017-04-04', 'studyFirstSubmitQcDate': '2012-10-11', 'lastUpdatePostDateStruct': {'date': '2017-08-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-04-04', 'studyFirstPostDateStruct': {'date': '2012-10-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-06-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2010-01-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8.', 'timeFrame': 'BL (Day 1) and Wk 8', 'description': 'This was an efficacy variable. An expert grader evaluated each side of the face (included forehead, cheeks and chin), the left and the right side, for IL (presence of papules and pustules), NIL (presence of open and closed comedones) and the TLs. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. The evaluator was also blinded. BL was defined as Day 1. The percent change was calculated as the value at Wk 8 minus the value at BL.'}], 'secondaryOutcomes': [{'measure': 'Mean Percent Change in IL Count From BL (Day 1) to Wks 1, 2 and 4', 'timeFrame': 'BL (Day1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the IL by counting the number of papules and pustules. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of IL) at each individual visit (percent value at wk 1, 2 and 4) minus the value at BL respectively.'}, {'measure': 'Mean Percent Change in NIL Count From BL (Day 1) to Wks 1, 2 and 4', 'timeFrame': 'BL (Day 1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the NIL by the presence of open and closed comedones. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of NIL) at each individual visit (percent value at Wk 1, 2 and 4) minus the value at BL respectively.'}, {'measure': 'Mean Percent Change in TL Count From BL (Day 1) to Wks 1, 2 and 4', 'timeFrame': 'BL (Day 1) to Wks 1, 2 and 4', 'description': 'This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the total lesions by the sum of both inflammatory and non-inflammatory lesions on each side (left side and right side). The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of total lesions) at each individual visit (percent value at Wks 1, 2 and 4) minus the value at baseline respectively.'}, {'measure': "Mean Change in Investigator's Static Global Assessment (ISGA) From BL (Day 1) to Wks 1, 2, 4 and 8.", 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "The evaluator (blinded) evaluated the acne severity of the participants' face using the ISGA scale ranging from 0 to 5. The grading was 0= Clear, skin with no IL or NILs; 1= Almost clear, rare NILs with no more than one small IL ; 2= Mild, some NILs with no more than few ILs (papules/pustules only, no nodular lesions); 3= Moderate Upto many NILs and may have some ILs but no more than one small nodular lesion ; 4= Severe, Upto many NILs and ILs but no more than a few nodular lesions; 5= Very severe, many NILS and ILs more than a few nodular lesions, may have cystic lesions. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each visit (Wks 1,2,4 and 8) minus the value at BL respectively."}, {'measure': 'Mean Change in Each of the Evaluator Tolerability Assessments-Erythema', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. Erythema is condition characterized by redness or rash on the skin. The assessment of the erythema was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk 4 and Wk 8, and hence statistical analysis was not done."}, {'measure': 'Mean Change in Each of the Evaluator Tolerability Assessments-Dryness', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the dryness was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at baseline respectively. The change from BL was '0' for Wk 2, Wk 4, and Wk 8 and hence statistical analysis was not done."}, {'measure': 'Mean Change in Each of the Evaluator Tolerability Assessments-Peeling', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': "This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the peeling was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk (1, 4 and 8) and hence statistical analysis was not done."}, {'measure': 'Mean Change in Each of the Participant Tolerability Assessments-Redness', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for redness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the redness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.'}, {'measure': 'Mean Change in Each of the Participant Assessments of Tolerability-Dryness', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for dryness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the dryness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.'}, {'measure': 'Mean Change in Each of the Participant Assessments of Tolerability-Burning', 'timeFrame': 'BL (Day 1) to Wks 1,2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for burning. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the burning was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1, 2, 4 and 8) minus the value at BL respectively.'}, {'measure': 'Mean Change in Each of the Participant Assessments of Tolerability-Itching', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for itching. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the itching was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.'}, {'measure': 'Mean Change in Each of the Participant Assessments of Tolerability-Scaling', 'timeFrame': 'BL (Day 1) to Wks 1, 2, 4 and 8', 'description': 'This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for scaling. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the scaling was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Acne Vulgaris']}, 'referencesModule': {'availIpds': [{'id': '114550', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Individual Participant Data Set', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '114550', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Annotated Case Report Form', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '114550', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Informed Consent Form', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '114550', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Clinical Study Report', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '114550', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Dataset Specification', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}], 'seeAlsoLinks': [{'url': 'https://www.clinicalstudydatarequest.com', 'label': 'Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.'}]}, 'descriptionModule': {'briefSummary': 'One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user.\n\nThe current study will evaluate and compare the efficacy and tolerability of 2 over-the-counter, topical benzoyl peroxide (BPO) product lines in subjects with acne: MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam compared with PROACTIV (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner.', 'detailedDescription': "Acne vulgaris is an extremely common dermatological disease that is found typically in adolescence and young adulthood. Acne vulgaris manifests with open and closed comedones (blackheads and whiteheads), papules, pustules, nodules, and cysts on the face, neck, and trunk. Scarring can occur, particularly if the lesions are inflamed and deep, even in the absence of external manipulation (eg, picking and squeezing) of the skin.\n\nAcne vulgaris can be treated with a variety of agents that are selected to address the pathogenic factors assumed to be responsible for the type and degree of manifested acne lesions. Monotherapy and combination therapy regimens are both useful. Topical agents are generally used as first-line therapy and include retinoids, antibiotic preparations (eg, erythromycin and clindamycin), benzoyl peroxide (BPO), alpha and beta hydroxy acids (eg, glycolic and salicylic acid preparations), and azelaic acid. Systemic therapies are initiated in patients with moderate to severe inflammatory acne that does not respond to topical therapy.\n\nBenzoyl peroxide has antimicrobial and anti inflammatory properties and is often considered an important component of acne treatment. Benzoyl peroxide is frequently the first product that adolescents will use for acne because it can be purchased without a prescription in several different concentrations and formulations.\n\nOne of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user.\n\nThe current study will evaluate and compare the efficacy and tolerability of 2 common, over-the-counter, topical benzoyl peroxide (BPO) product lines in subjects with acne: MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam compared with PROACTIV(2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner.\n\nThis is a randomized, 2 center, evaluator-blinded, split-face efficacy and tolerability study of MAXCLARITYII and PROACTIV, 2 over-the-counter, topical benzoyl peroxide product lines, in subjects with acne. Approximately 40 subjects, aged from 16 to 29 years, inclusive, with mild facial acne vulgaris are expected to participate in the study. No more than 50% of the subjects at each site can be enrolled under the age of 20.\n\nAn expert grader (blinded evaluator) will complete counts of inflamed lesions (papules/pustules) and noninflamed lesions (open/closed comedones), the Investigator's Static Global Assessment (ISGA), and an assessment of tolerability of each side of the face at each study visit. Subjects will assess tolerability on each side of the face at each study visit and will complete a product acceptability and preference questionnaire at the end of the study.\n\nThe study duration will be 8 weeks (56 days) with visits at baseline (day 1), week 1m week 2, week 4 and week 8. Only the expert grader (evaluator) will be blinded to the study product assignments; subjects and study nurses/coordinator will not be blinded."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '29 Years', 'minimumAge': '16 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed.\n2. Male or female aged from 16 to 29 years, inclusive, at time of consent. No more than 50% of the subjects at each site can be enrolled under the age of 20.\n3. Mild facial acne vulgaris, characterized by at least 12 facial inflammatory lesions (papules and pustules) and/or noninflammatory lesions (open and closed comedones) on the face.\n4. Able to complete the study and to comply with study instructions.\n5. Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Acceptable contraceptive methods include the following:\n\n * Hormonal contraception, including oral, injectable, or implantable methods started at least 2 months prior to screening. If hormonal contraception was started less than 2 months prior to screening, then a form of nonhormonal contraception should be added until the third continuous month of hormonal contraception has been completed.\n * Two forms of reliable nonhormonal contraception, to include the use of either an intrauterine device plus a reliable barrier method or 2 reliable barrier methods. Reliable barrier methods include condoms or diaphragms. A cervical cap is also a reliable barrier method, provided that the female subject has never given birth naturally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Subjects with surgical sterilization, including tubal sterilization or partner's vasectomy, must use a form of nonhormonal contraception. A barrier method or sterilization plus spermatocide is acceptable.\n * Women who are not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the study.\n\nExclusion Criteria:\n\n1. Female who is pregnant, trying to become pregnant, or breast feeding.\n2. Has active or chronic skin allergies.\n3. Has a history of acute or chronic disease that might interfere with or increase the risk of study participation.\n4. Had skin cancer treatment in preceding 12 months.\n5. Has damaged skin on facial areas (eg, sunburn, tattoo, or scar)\n6. Had any medical procedure (eg, laser resurfacing, chemical peel, or plastic surgery) on facial areas in preceding 12 months.\n7. Had any cosmetic procedure (eg, microdermabrasion) on facial areas within 8 weeks of the baseline visit.\n8. Has any dermatological disorder that in the opinion of the investigator may interfere with the accurate evaluation of the subject's facial appearance.\n9. Received any investigational drug or procedure within 28 days of the baseline visit or is scheduled to receive an investigational drug (other than the study products) or procedure during the study.\n10. Currently using any medication that in the opinion of the investigator may affect the evaluation of the study products or place the subject at undue risk (including but not limited to asthma medications, oral steroids, rifampin, anticonvulsants, and St John's wart).\n11. Has a history of known or suspected intolerance to any of the ingredients of the study products (ie, benzoyl peroxide).\n12. Considered unable or unlikely to attend the necessary visits.\n13. Live in the same household as currently enrolled subjects.\n14. Employee of the investigator, a contract research organization, or Stiefel Laboratories who is involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study."}, 'identificationModule': {'nctId': 'NCT01706250', 'briefTitle': 'U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™', 'organization': {'class': 'INDUSTRY', 'fullName': 'GlaxoSmithKline'}, 'officialTitle': 'U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects With Acne', 'orgStudyIdInfo': {'id': '114550'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MAXCLARITY II', 'description': 'MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.', 'interventionNames': ['Other: MAXCLARITY II (2.5% BPO) Foam Cleanser', 'Other: MAXCLARITY II (2.5% BPO) Foam Treatment', 'Other: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'PROACTIV', 'description': 'Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.', 'interventionNames': ['Other: PROACTIV (2.5% BPO) Renewing Cleanser', 'Other: PROACTIV (2.5% BPO) Repairing Lotion', 'Other: PROACTIV (2.5% BPO) Revitalizing Toner']}], 'interventions': [{'name': 'MAXCLARITY II (2.5% BPO) Foam Cleanser', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['MAXCLARITY II']}, {'name': 'MAXCLARITY II (2.5% BPO) Foam Treatment', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['MAXCLARITY II']}, {'name': 'MAXCLARITY II (0.5% Salicylic Acid) Toner Foam', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['MAXCLARITY II']}, {'name': 'PROACTIV (2.5% BPO) Renewing Cleanser', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['PROACTIV']}, {'name': 'PROACTIV (2.5% BPO) Repairing Lotion', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['PROACTIV']}, {'name': 'PROACTIV (2.5% BPO) Revitalizing Toner', 'type': 'OTHER', 'description': 'Available over the counter.', 'armGroupLabels': ['PROACTIV']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'GSK Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'GlaxoSmithKline'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Stiefel, a GSK Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}